Brief: Zai Lab Announces NDA Acceptance Of Repotrectinib By China's NMPA
June 28 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB ANNOUNCES NDA ACCEPTANCE OF REPOTRECTINIB FOR
PATIENTS
WITH ROS1-POSITIVE NSCLC BY CHINA’S NMPA
Source text for Eikon: ID:nGNX6TSqfm
Further company coverage: 9688.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows